{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:23:04Z","timestamp":1791397384889,"version":"4.3.3"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.hoc.2008.07.010","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T09:21:01Z","timestamp":1225185661000},"page":"997-1005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Peripheral T-Cell Non-Hodgkin's Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Julie M.","family":"Vose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2008.07.010_bib1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: the Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2008.07.010_bib3","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/00042560-199600001-00004","article-title":"Adult T-cell leukemia in Japan","volume":"13","author":"Takatsuki","year":"1996","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1016\/j.hoc.2008.07.010_bib4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood.V96.2.443","article-title":"Fulminant EBV + T-cell lymphoproliferative disorders following acute\/chronic EBV infection: a distinct clinicopathologic syndrome","volume":"96","author":"Quintanilla-Martinez","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib5","series-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"key":"10.1016\/j.hoc.2008.07.010_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project","volume":"13","author":"Rudiger","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2008.07.010_bib7","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicenter clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2008.07.010_bib9","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin's lymphoma","volume":"103","author":"Escalon","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2008.07.010_bib10","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2008.07.010_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1532\/IJH97.05188","article-title":"Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide","volume":"83","author":"Yamaguchi","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1016\/j.hoc.2008.07.010_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2008.07.010_bib14","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.010_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin's lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2008.07.010_bib16","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2008.07.010_bib17","doi-asserted-by":"crossref","first-page":"3061a","DOI":"10.1200\/jco.2005.23.16_suppl.3061","article-title":"Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228","volume":"23","author":"Piekarz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.010_bib18","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.010_bib19","doi-asserted-by":"crossref","first-page":"400a","DOI":"10.1182\/blood.V108.11.400.400","article-title":"Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphomas: results of the MSKCC phase I\/II experience","volume":"108","author":"O'Connor","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2008.07.010_bib21","doi-asserted-by":"crossref","first-page":"1906a","DOI":"10.1182\/blood.V110.11.1906.1906","article-title":"Long term results of autologous hematopoietic cell transplantation (AHCT) for peripheral T-cell lymphoma: the Stanford experience","volume":"110","author":"Chen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo-Study Group","volume":"79","author":"Rodriguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2008.07.010_bib23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.thj.6200359","article-title":"Myeloablative radiochemotherpy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study","volume":"5","author":"Reimer","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.hoc.2008.07.010_bib24","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societ\u00e9 Francaise of Greffe de Moelle et de Therapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.010_bib25","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.010_bib26","doi-asserted-by":"crossref","first-page":"811a","DOI":"10.1182\/blood.V106.11.811.811","article-title":"International Peripheral T-cell Lymphoma Study: clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracylines","volume":"106","author":"Vose","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/oxfordjournals.annonc.a059281","article-title":"Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation: the Kiel Lymphoma Study Group","volume":"6","author":"Siegert","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2008.07.010_bib28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/10428190290016926","article-title":"T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors","volume":"43","author":"Reiser","year":"2002","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.hoc.2008.07.010_bib29","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T-cell lymphoma: treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2008.07.010_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.thj.6200136","article-title":"Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma","volume":"2","author":"Quintini","year":"2001","journal-title":"Hematol J"},{"key":"10.1016\/j.hoc.2008.07.010_bib32","first-page":"2697","article-title":"ALK+ lymphoma: clinico-pathological findings and outcome","volume":"93","author":"Falini","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib33","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood.V87.9.3860.bloodjournal8793860","article-title":"Occurrence of the t(2;5)(p23p35) in non-Hodgkin's lymphoma","volume":"87","author":"Weisenburger","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib34","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1996.14.3.955","article-title":"Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients","volume":"14","author":"Zinzani","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.010_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00000478-199601000-00012","article-title":"Report of the workshop on nasal and related extranodal angiocentric T\/natural killer cell lymphomas: definitions, differential diagnosis, and epidemiology","volume":"20","author":"Jaffe","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.hoc.2008.07.010_bib36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.1998.16.1.70","article-title":"Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunphenotype, and treatment outcome of 113 patients","volume":"16","author":"Cheung","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.010_bib37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0167-8140(01)00428-5","article-title":"Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck","volume":"61","author":"Kim","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.hoc.2008.07.010_bib38","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic \u03b3\u03b4 T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0198-8859(94)00130-I","article-title":"HLA-DRB, DQA, and DQB polymorphism in celiac disease and Enteropathy-associated T-cell lymphoma: common features and additional risk factors for malignancy","volume":"43","author":"Howell","year":"1995","journal-title":"Hum Immunol"},{"key":"10.1016\/j.hoc.2008.07.010_bib40","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/00000478-199807000-00010","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha\/beta and gamma\/delta subtypes","volume":"22","author":"Salhany","year":"1998","journal-title":"Am J Surg Pathol."},{"key":"10.1016\/j.hoc.2008.07.010_bib41","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 patients","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib42","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984\u20131987)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2008.07.010_bib43","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V74.1.388.388","article-title":"Infection of human T-cell leukemia virus type I\u00a0and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion","volume":"74","author":"Chen","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-0609.2007.01016.x","article-title":"Treatment of adult T-cell leukemia\/lymphoma: past, present, and future","volume":"80","author":"Ishitsuka","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2008.07.010_bib45","doi-asserted-by":"crossref","first-page":"3409a","DOI":"10.1182\/blood.V110.11.3409.3409","article-title":"Zanolimumab (HuMax CD4), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma","volume":"110","author":"d'Amore","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib46","doi-asserted-by":"crossref","first-page":"2727a","DOI":"10.1182\/blood.V108.11.2727.2727","article-title":"A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma\/leukemia","volume":"108","author":"Casale","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib47","doi-asserted-by":"crossref","first-page":"4492a","DOI":"10.1182\/blood.V110.11.4492.4492","article-title":"Phase I study of KW-0761, a humanized anti-CCR4 antibody in patients with relapsed or refractory adult T-cell leukemia\/lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL): preliminary results","volume":"110","author":"Uike","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib48","doi-asserted-by":"crossref","first-page":"2637a","DOI":"10.1182\/blood.V104.11.2637.2637","article-title":"SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma","volume":"104","author":"Forero-Torres","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib49","doi-asserted-by":"crossref","first-page":"2636a","DOI":"10.1182\/blood.V104.11.2636.2636","article-title":"Phase I\/II open-label dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory\/relapsed CD30 positive lymphoma","volume":"104","author":"Ansell","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.010_bib50","doi-asserted-by":"crossref","first-page":"690a","DOI":"10.1182\/blood.V110.11.690.690","article-title":"Syk tyrosine kinase is overexpressed in the majority of peripheral T- and NK-cell lymphomas, and represents a potential therapeutic target","volume":"110","author":"Feldman","year":"2007","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858808001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858808001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:52:57Z","timestamp":1760183577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858808001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0889858808001068"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2008.07.010","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral T-Cell Non-Hodgkin's Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2008.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}